Table 4.
Multivariate analysis of MYC and BCL2 coexpression and prognostic scoring systems for progression-free survival in patients with PCNS-DLBCL treated with combined MVP and radiotherapy
| PFS | |||
|---|---|---|---|
| HR | 95 % CI | P | |
| Age | 0.983 | 0.922–1.049 | 0.605 |
| N-B, 2–3 | 1.146 | 0.464–2.830 | 0.768 |
| MSKCC, 2–3 | 4.975 | 0.715–34.613 | 0.105 |
| MYC (≥40) and BCL2 (≥60), dual positive | 4.372 | 1.430–13.367 | 0.010 |
Abbreviations: PFS progression-free survival, HR hazard ratio, CI confidence interval, N-B Nottingham- Barcelona, MSKCC Memorial Sloan Kettering Cancer Center